DNB Asset Management AS Purchases 16,267 Shares of Glaukos Corporation $GKOS

DNB Asset Management AS lifted its position in shares of Glaukos Corporation (NYSE:GKOS) by 28.4% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 73,550 shares of the medical instruments supplier’s stock after buying an additional 16,267 shares during the quarter. DNB Asset Management AS owned approximately 0.13% of Glaukos worth $5,998,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. AQR Capital Management LLC raised its holdings in shares of Glaukos by 2.6% in the first quarter. AQR Capital Management LLC now owns 7,788 shares of the medical instruments supplier’s stock valued at $766,000 after acquiring an additional 198 shares in the last quarter. Jones Financial Companies Lllp increased its position in Glaukos by 1,405.9% during the 1st quarter. Jones Financial Companies Lllp now owns 2,560 shares of the medical instruments supplier’s stock valued at $252,000 after purchasing an additional 2,390 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in shares of Glaukos by 41.7% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 229,994 shares of the medical instruments supplier’s stock valued at $22,636,000 after purchasing an additional 67,668 shares in the last quarter. AlphaQuest LLC lifted its position in shares of Glaukos by 5,754.5% in the 2nd quarter. AlphaQuest LLC now owns 644 shares of the medical instruments supplier’s stock worth $67,000 after purchasing an additional 633 shares during the period. Finally, Envestnet Asset Management Inc. boosted its stake in shares of Glaukos by 72.8% during the second quarter. Envestnet Asset Management Inc. now owns 48,439 shares of the medical instruments supplier’s stock valued at $5,003,000 after purchasing an additional 20,401 shares in the last quarter. Hedge funds and other institutional investors own 99.04% of the company’s stock.

Insider Transactions at Glaukos

In other Glaukos news, COO Joseph E. Gilliam sold 10,498 shares of the company’s stock in a transaction that occurred on Thursday, January 22nd. The shares were sold at an average price of $127.68, for a total transaction of $1,340,384.64. Following the transaction, the chief operating officer owned 92,366 shares in the company, valued at approximately $11,793,290.88. This represents a 10.21% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Marc Stapley sold 15,000 shares of Glaukos stock in a transaction on Thursday, January 22nd. The stock was sold at an average price of $127.71, for a total transaction of $1,915,650.00. Following the sale, the director owned 37,449 shares of the company’s stock, valued at $4,782,611.79. The trade was a 28.60% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 325,000 shares of company stock worth $37,739,259 over the last ninety days. 6.40% of the stock is currently owned by insiders.

Glaukos Stock Down 1.2%

Glaukos stock opened at $120.01 on Monday. Glaukos Corporation has a 1-year low of $73.16 and a 1-year high of $130.23. The business has a fifty day moving average price of $116.00 and a 200-day moving average price of $100.15. The company has a debt-to-equity ratio of 0.10, a current ratio of 4.69 and a quick ratio of 4.06. The stock has a market capitalization of $6.97 billion, a price-to-earnings ratio of -36.81 and a beta of 0.70.

Glaukos (NYSE:GKOS) last announced its earnings results on Tuesday, February 17th. The medical instruments supplier reported ($0.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.22) by ($0.06). The business had revenue of $143.12 million for the quarter, compared to analyst estimates of $132.16 million. Glaukos had a negative net margin of 36.99% and a negative return on equity of 7.00%. The company’s quarterly revenue was up 35.6% on a year-over-year basis. During the same period in the prior year, the company earned ($0.40) earnings per share. Equities research analysts forecast that Glaukos Corporation will post -1.08 EPS for the current fiscal year.

Analysts Set New Price Targets

GKOS has been the subject of a number of recent research reports. The Goldman Sachs Group reissued a “buy” rating and issued a $138.00 price objective on shares of Glaukos in a research note on Friday, January 9th. Wall Street Zen downgraded Glaukos from a “buy” rating to a “hold” rating in a report on Saturday, February 21st. Citigroup upped their price objective on Glaukos from $113.00 to $125.00 and gave the stock a “buy” rating in a research note on Thursday, December 11th. William Blair raised Glaukos to a “strong-buy” rating in a research report on Friday, January 30th. Finally, Needham & Company LLC boosted their target price on shares of Glaukos from $125.00 to $127.00 and gave the stock a “buy” rating in a report on Wednesday, February 18th. One investment analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, Glaukos has a consensus rating of “Moderate Buy” and an average price target of $133.69.

About Glaukos

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.